Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female ≥ 18 years, ≤70 years.~* Minimum life expectancy 16 weeks~* Histologicalconfirmation of hormone receptor negative and HER2 negative breast cancer(IHC:ER -, PR-) on primary tumour at diagnosis/on biopsy of metastasis~* Clinical or histological confirmation of metastatic or locally advanced disease not amenable to curative surgical resection~* ECOG 0-2 with no deterioration over previous 2 weeks Measurable disease~* Adequate bone marrow and organ function~* Availability of archival tumour sample or fresh biopsy Informed consent~* Normal organ function~Exclusion Criteria:~* Last dose chemotherapy, immunotherapy targeted therapy, biological therapy or tumour embolisation \<21 days prior to study treatment~* Last dose of palliative radiotherapy \<7 days prior to study treatment~* Rapidly progressive visceral disease not suitable for further therapy~* Spinal cord compression or brain/meningeal metastases unless asymptomatic, treated and stable and not requiring steroids for ≥ 4 weeks study treatment~* Major surgery (excluding placement of vascular access) within 4 weeks before study treatment~* Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and HIV~* With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment~* Elevated ALP in absence of bone metastasis~* Evidence of dementia, altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent~* Participation in another study with investigational product during last 30 days~* Inability or unwillingness to comply with study procedures, including inability to take regular oral medication

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Epalrestat (Type: EXPERIMENTAL): Epalrestat added to standard treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).